Appropriate Use Criteria for Nuclear Medicine in the Evaluation and Treatment of Differentiated Thyroid Cancer
J Nucl Med
.
2020 Mar;61(3):375-396.
doi: 10.2967/jnumed.119.240945.
Authors
Kevin J Donohoe
1
,
Jennifer Aloff
2
,
Anca M Avram
3
,
K G Bennet
3
,
Luca Giovanella
4
,
Bennett Greenspan
5
,
Seza Gulec
5
,
Aamna Hassan
5
,
Richard T Kloos
6
,
Carmen C Solórzano
7
,
Brendan C Stack Jr
8
,
Mark Tulchinsky
5
,
Robert Michael Tuttle
9
,
Douglas Van Nostrand
5
,
Jason A Wexler
10
Affiliations
1
Society of Nuclear Medicine and Molecular Imaging, Reston, Virginia
[email protected]
.
2
American Academy of Family Physicians, Washington, DC.
3
American College of Nuclear Medicine, Reston, Virginia.
4
European Association of Nuclear Medicine, Vienna, Austria.
5
Society of Nuclear Medicine and Molecular Imaging, Reston, Virginia.
6
American Thyroid Association, Falls Church, Virginia.
7
American Association of Endocrine Surgeons, Lexington, Kentucky.
8
American Head and Neck Society, Los Angeles, California.
9
American Association of Clinical Endocrinologists, Jacksonsville, Florida; and.
10
Endocrine Society, Washington, DC.
PMID:
32123131
DOI:
10.2967/jnumed.119.240945
No abstract available
MeSH terms
Diagnostic Imaging
Humans
Neoplasm Staging
Nuclear Medicine / standards*
Radiometry
Reference Standards
Thyroid Neoplasms / diagnostic imaging*
Thyroid Neoplasms / pathology
Thyroid Neoplasms / radiotherapy*